M3VAS test validation for depression and bipolar disorder
Part of Brain & nervous system, Mental health clinical trials.
This study is testing a tool called M3VAS to see how well it measures depression and bipolar disorder symptoms in the Polish population. It might help doctors better understand your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with major depressive disorder or bipolar disorder.
- You do not have a psychotic disorder (like schizophrenia).
- You are not currently experiencing mania or hypomania (extreme high moods) as part of bipolar disorder.
- You are able to complete questionnaires and assessments in Polish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tracking your daily activity can help improve energy and mood in people with depression. You will wear a small device that measures your movement.
This study tests a new blood test (EDIT-B®) to help doctors tell the difference between depression and bipolar disorder. If you have a depressive episode but there is doubt about bipolar disorder, this test might help guide your treatment to improve your health.
This trial tests whether three psychiatric questionnaires work well for people with schizophrenia or related disorders. If you are between 18 and 65 and have one of these diagnoses, joining may help improve care for others like you.
This trial tests a new medical device that uses a blood test to help doctors accurately diagnose bipolar disorder in people who were thought to have major depression. It aims to see if the device can tell the difference and improve treatment choices.
This study uses a mobile app and brain scans to understand day-to-day mood changes in people with depression or bipolar disorder. It may help doctors learn how to better predict and treat these conditions.
This study looks at treatment response markers (signs in the body) in people with major depressive disorder (MDD). It may help researchers understand who is more likely to benefit from antidepressant treatment.
Hear when a new Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.